▟ Vinebot intrinsic value, daily

← back

RVTY Revvity

healthcare · valued with opus low conviction · deep-dived 2026-11-11

SELL
Intrinsic value$54.28
Price (at call)$159.10
Margin of safety -65.9%
vs market (rating basis) -43.9%

Solid consumables franchise, but $159 assumes margins and growth well above what post-COVID tools economics support.

The story

Revvity is a life sciences tools and diagnostics company (reagents, immunodiagnostics, newborn screening, software) that emerged from PerkinElmer's breakup. Its moat comes from recurring consumables and razor/blade installed bases, and BioLegend reagents and newborn screening give it real niche franchises. After the COVID revenue cliff it is now a mature, mid-single-digit grower. Reported margins are depressed by roughly $280M a year of acquisition amortization, which hides underlying cash economics in the mid-20s.

The 0.28 trailing sales-to-capital and 11% GAAP margin reflect goodwill and amortization from past deals, not incremental economics. I use a 26% target margin, which approximates pre-amortization peer-level tools economics short of the ~28% adjusted peak, and 1.5 incremental sales-to-capital for a consumables-heavy model. Growth of 5-6% reflects post-COVID normalization with a recovery in biopharma and China spending, and the 10-year horizon credits the recurring-revenue franchise without treating it as a wide-moat compounder.

Value drivers

Revenue growth (Y1)5.0%
Terminal growth3.0%
Forecast horizon10y
Target operating margin26.0%
Years to target margin5
Sales-to-capital1.50
Beta0.95
Failure probability2.0%
Cost of capital (WACC)9.3%
Terminal WACC9.5%

Valuation bridge

PV of explicit FCFF4.00B
PV of terminal value4.49B
Equity value6.06B
÷ shares → per share$54.28

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 3.06B 5.0% 14.2% 387.40M 97.06M 290.34M 265.68M
2 3.20B 4.8% 17.1% 490.62M 97.38M 393.24M 329.28M
3 3.35B 4.6% 20.1% 601.54M 97.29M 504.25M 386.38M
4 3.49B 4.3% 23.0% 720.01M 96.76M 623.25M 437.01M
5 3.64B 4.1% 26.0% 845.82M 95.78M 750.04M 481.25M
6 3.78B 3.9% 26.0% 878.71M 94.32M 784.39M 460.55M
7 3.92B 3.7% 26.0% 910.93M 92.39M 818.54M 439.78M
8 4.05B 3.4% 26.0% 942.31M 89.98M 852.33M 419.05M
9 4.18B 3.2% 26.0% 972.67M 87.07M 885.60M 398.43M
10 4.31B 3.0% 26.0% 1.00B 83.68M 918.18M 378.00M

Key risks

  • China diagnostics volume-based procurement and reimbursement cuts compress the immunodiagnostics business
  • NIH and academic funding cuts plus a weak biotech funding environment stall life sciences reagent demand
  • Leverage (2.3B net debt) and buyback-funded EPS growth mask organic stagnation; another large acquisition at a high multiple destroys value

Catalysts

  • Biopharma and academic tools demand recovers and lifts organic growth back to 6%+
  • Margin expansion toward 28%+ adjusted operating margin from cost actions and software (Signals) mix

History

DatePriceIntrinsicMoSRating
2026-11-11$159.10 $54.28 -65.9% SELL
2026-09-22$143.59 $2.73 -98.1% STRONG SELL
2026-08-03$112.52 $11.31 -89.9% STRONG SELL
2026-06-23$99.90 $10.71 -89.3% STRONG SELL